Cognition in movement disorders: where can we hope to be in ten years?
Identifieur interne : 000521 ( PubMed/Corpus ); précédent : 000520; suivant : 000522Cognition in movement disorders: where can we hope to be in ten years?
Auteurs : David Burn ; Daniel Weintraub ; Bernard Ravina ; Irene LitvanSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2014.
English descriptors
- KwdEn :
- Animals, Biological Markers, Cognition (physiology), Cognition Disorders (complications), Cognition Disorders (diagnosis), Cognition Disorders (therapy), Dementia (complications), Dementia (diagnosis), Dementia (therapy), Humans, Movement Disorders (diagnosis), Movement Disorders (etiology), Movement Disorders (therapy).
- MESH :
- chemical : Biological Markers.
- complications : Cognition Disorders, Dementia.
- diagnosis : Cognition Disorders, Dementia, Movement Disorders.
- etiology : Movement Disorders.
- physiology : Cognition.
- therapy : Cognition Disorders, Dementia, Movement Disorders.
- Animals, Humans.
Abstract
Cognitive impairment and dementia associated with movement disorders represent a major management challenge and area of unmet need. This article has focused upon Parkinson's disease as an exemplar condition, but many of the roadblocks and efforts to overcome these are applicable, in a general sense, to other disorders. Short of a "penicillin moment"-a chance discovery or piece of unintended good fortune-progress is likely to be incremental. Cognitive therapies may end up being multiple and possibly multimodal, parallel with the cancer therapy field. Ultimately, benefit for one condition may extend to others as commonality in protein aggregation, synergistic pathological effects between proteins, and pathological spread emerges. © 2014 International Parkinson and Movement Disorder Society.
DOI: 10.1002/mds.25850
PubMed: 24757118
Links to Exploration step
pubmed:24757118Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cognition in movement disorders: where can we hope to be in ten years?</title><author><name sortKey="Burn, David" sort="Burn, David" uniqKey="Burn D" first="David" last="Burn">David Burn</name><affiliation><nlm:affiliation>Institute for Aging and Health, Newcastle University, Newcastle upon Tyne, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name></author><author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name></author><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="doi">10.1002/mds.25850</idno><idno type="RBID">pubmed:24757118</idno><idno type="pmid">24757118</idno><idno type="wicri:Area/PubMed/Corpus">000521</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cognition in movement disorders: where can we hope to be in ten years?</title><author><name sortKey="Burn, David" sort="Burn, David" uniqKey="Burn D" first="David" last="Burn">David Burn</name><affiliation><nlm:affiliation>Institute for Aging and Health, Newcastle University, Newcastle upon Tyne, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name></author><author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name></author><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Biological Markers</term><term>Cognition (physiology)</term><term>Cognition Disorders (complications)</term><term>Cognition Disorders (diagnosis)</term><term>Cognition Disorders (therapy)</term><term>Dementia (complications)</term><term>Dementia (diagnosis)</term><term>Dementia (therapy)</term><term>Humans</term><term>Movement Disorders (diagnosis)</term><term>Movement Disorders (etiology)</term><term>Movement Disorders (therapy)</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Biological Markers</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Cognition Disorders</term><term>Dementia</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cognition Disorders</term><term>Dementia</term><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Cognition</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Cognition Disorders</term><term>Dementia</term><term>Movement Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cognitive impairment and dementia associated with movement disorders represent a major management challenge and area of unmet need. This article has focused upon Parkinson's disease as an exemplar condition, but many of the roadblocks and efforts to overcome these are applicable, in a general sense, to other disorders. Short of a "penicillin moment"-a chance discovery or piece of unintended good fortune-progress is likely to be incremental. Cognitive therapies may end up being multiple and possibly multimodal, parallel with the cancer therapy field. Ultimately, benefit for one condition may extend to others as commonality in protein aggregation, synergistic pathological effects between proteins, and pathological spread emerges. © 2014 International Parkinson and Movement Disorder Society.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24757118</PMID><DateCreated><Year>2014</Year><Month>04</Month><Day>23</Day></DateCreated><DateCompleted><Year>2014</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2015</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Cognition in movement disorders: where can we hope to be in ten years?</ArticleTitle><Pagination><MedlinePgn>704-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.25850</ELocationID><Abstract><AbstractText>Cognitive impairment and dementia associated with movement disorders represent a major management challenge and area of unmet need. This article has focused upon Parkinson's disease as an exemplar condition, but many of the roadblocks and efforts to overcome these are applicable, in a general sense, to other disorders. Short of a "penicillin moment"-a chance discovery or piece of unintended good fortune-progress is likely to be incremental. Cognitive therapies may end up being multiple and possibly multimodal, parallel with the cancer therapy field. Ultimately, benefit for one condition may extend to others as commonality in protein aggregation, synergistic pathological effects between proteins, and pathological spread emerges. © 2014 International Parkinson and Movement Disorder Society.</AbstractText><CopyrightInformation>© 2014 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Aging and Health, Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ravina</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Litvan</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5R01AG024040</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Neurol Sci. 2006 Nov 1;249(1):31-8</RefSource><PMID Version="1">16843494</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2005 Jul;76(7):934-9</RefSource><PMID Version="1">15965198</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 Oct 15;23(13):1867-74</RefSource><PMID Version="1">18759361</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharm Res. 2009 Jan;26(1):1-18</RefSource><PMID Version="1">18841450</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Cogn. 2009 Mar;69(2):435-41</RefSource><PMID Version="1">19006643</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Metab Dispos. 2009 Mar;37(3):635-43</RefSource><PMID Version="1">19047468</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2009 Jun;66(6):781-5</RefSource><PMID Version="1">19506141</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2009 Jul;8(7):613-8</RefSource><PMID Version="1">19520613</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharmacol. 2009 Sep 1;617(1-3):54-8</RefSource><PMID Version="1">19576880</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2009 Nov;132(Pt 11):2958-69</RefSource><PMID Version="1">19812213</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann N Y Acad Sci. 2010 Jan;1184:188-95</RefSource><PMID Version="1">20146698</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2010 Sep;68(3):311-8</RefSource><PMID Version="1">20818789</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2010 Sep 21;75(12):1055-61</RefSource><PMID Version="1">20720189</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2010 Oct;9(10):969-77</RefSource><PMID Version="1">20729148</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2010 Oct;68(4):521-34</RefSource><PMID Version="1">20687206</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Neurol Scand. 2011 Jan;123(1):13-9</RefSource><PMID Version="1">20199518</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Dec 15;25(16):2756-61</RefSource><PMID Version="1">20939079</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(4):e19338</RefSource><PMID Version="1">21559417</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Alzheimers Dement. 2011 May;7(3):257-62</RefSource><PMID Version="1">21514247</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2011 Jul 8;146(1):37-52</RefSource><PMID Version="1">21700325</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2011 Jul 6;31(27):10076-87</RefSource><PMID Version="1">21734300</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropharmacology. 2012 Feb;62(2):1099-110</RefSource><PMID Version="1">22085888</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropsychol. 2012;26(1):45-58</RefSource><PMID Version="1">22150514</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2012 Sep 1;27(10):1230-8</RefSource><PMID Version="1">22915447</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Aging. 2012 Jun;33(6):1127.e11-20</RefSource><PMID Version="1">22226489</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sci Transl Med. 2012 Feb 15;4(121):121ra20</RefSource><PMID Version="1">22344688</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2012 Sep 15;27(11):1392-7</RefSource><PMID Version="1">22976926</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stat Med. 2012 Nov 10;31(25):3011-23</RefSource><PMID Version="1">22927234</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2012 Oct;72(4):587-98</RefSource><PMID Version="1">23037886</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2012 May;69(5):636-43</RefSource><PMID Version="1">22232206</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2013 Jan 1;80(1):85-91</RefSource><PMID Version="1">23243071</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2013 Feb 5;158(3):162-8</RefSource><PMID Version="1">23381040</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2013 Jan;28(1):14-23</RefSource><PMID Version="1">23389780</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Neurol. 2013 Feb;70(2):223-8</RefSource><PMID Version="1">23407718</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Neurol. 2013 Jun;70(6):727-35</RefSource><PMID Version="1">23588557</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2013 Jul;12(7):716-26</RefSource><PMID Version="1">23769598</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2013 Sep;19(9):812-7</RefSource><PMID Version="1">23773412</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pharm Sci. 2013 Sep;102(9):3343-55</RefSource><PMID Version="1">23650139</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2013 Jul;28(8):1034-49</RefSource><PMID Version="1">23426759</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2013 Aug 27;81(9):801-7</RefSource><PMID Version="1">23892706</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2013 Sep 10;81(11):971-6</RefSource><PMID Version="1">23921884</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2013 Sep 18;79(6):1094-108</RefSource><PMID Version="1">24050400</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2013 Oct 8;81(15):1284-90</RefSource><PMID Version="1">24014503</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Exp Neuropsychol. 2013;35(9):926-33</RefSource><PMID Version="1">24074137</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Alzheimers Dement. 2013 Nov;9(6):666-76</RefSource><PMID Version="1">23411393</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2676-88</RefSource><PMID Version="1">24035740</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2666-75</RefSource><PMID Version="1">24060532</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Neurol. 2013 Oct;70(10):1277-87</RefSource><PMID Version="1">23979011</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2004 Dec 9;351(24):2509-18</RefSource><PMID Version="1">15590953</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Clin Neuropsychol. 2007 Nov;22(8):957-67</RefSource><PMID Version="1">17851032</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003071">Cognition</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003072">Cognition Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003704">Dementia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009069">Movement Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS671144</OtherID><OtherID Source="NLM">PMC4371593</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">cognitive testing</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">therapeutics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25850</ArticleId><ArticleId IdType="pubmed">24757118</ArticleId><ArticleId IdType="pmc">PMC4371593</ArticleId><ArticleId IdType="mid">NIHMS671144</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000521 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000521 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24757118
|texte= Cognition in movement disorders: where can we hope to be in ten years?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24757118" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |